Find Clinical Trials

Advanced Search

Study phase

Document

Therapeutic area group

Indication

SEARCH CLEAR

179 Results

Protocol Code Study Title Active Substance Study Phase Therapeutic Area
CL3-95008-002 Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less… BUMETANIDE / S095008 / Phase 3 Neurosciences
CL3-95008-001 Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7… BUMETANIDE / S095008 / Phase 3 Neurosciences
CL2-201086-002 Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with… S201086 / Phase 2 Rhumatology
Control-2 Efficacy of ivabradine in combination with beta-blockers vs up-titration of beta-blockers in daily practice IVABRADINE - S016257 / Phase 4 Cardiovascular
CL3-05153-008 A clinical study to test the safety and the efficacy of a single-pill combination of… AMLODIPINE / ATORVASTATIN / ATORVASTATIN - AMLODIPINE - PERINDOPRIL ARGININE - S005153 / PERINDOPRIL / S005153 / Phase 3 Cardiovascular
CL3-05682-109 Clinical non-inferiority study between Micronized purified flavonoid fraction 1000 mg, one chewable tablet per day… MICRONISED PURIFIED FLAVONOID FRACTION / S005682 / Phase 3 Cardiovascular
CL1-95010-001 Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy… S095010 / Phase 1 Cardiovascular
CL3-95005-006 An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to… TIPIRACIL / TRIFLURIDINE / TRIFLURIDINE - TIPIRACIL / Phase 3 Oncology
CL1-81694-003 Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the… S081694 / Phase 1-2 Oncology
CL1-49076-002 Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with… S049076 / Phase 1-2 Oncology
CL1-80881-002 INES - Phase Ib dose allocation study of oral administration of lucitanib given in combination… LUCITANIB / Phase 1 Oncology
CL1-68587-001 A phase 1, open label, non-comparative, monocenter study to evaluate the safety and the ability… S068587 / S068587 - UCART19 / UCART19 / Phase 1 Oncology
IC4-95005-183-DEU Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life… TIPIRACIL / TRIFLURIDINE / TRIFLURIDINE - TIPIRACIL / Phase 4 Oncology
SC3-90049-001 Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg… PIRIBEDIL / Phase 3 Neurosciences
SC2-90049-003 Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil… PIRIBEDIL / Phase 2 Neurosciences
PKH-05720-001 A study to assess the release profiles from fixed combination tablets (gliclazide MR/metformin) GLICLAZIDE / GLICLAZIDE - METFORMINE - S005720 / METFORMINE / S005720 / Phase 1 Metabolism
MC3-06790-001 Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of… TRIMETAZIDINE / Phase 3 Cardiovascular
IC4-5702-205-CHN Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat… Phase 4 Metabolism
IC4-20098-542 Efficacy and safety of ValdoxanR given orally once a day for 24 weeks in patients… AGOMELATINE / AGOMELATINE - S020098 / S020098 / Phase 4 Neurosciences
IC4-12911-098 PRotelos 2g in the OSteoporosis treatment, the Tolerability and Efficacy Profile - PROSTEP STRONTIUM / STRONTIUM RANELATE / Phase 4 Rhumatology
IC4-05682-099 Efficacy of Detralex® in Edema Treatment. An open, 6-month, multicentre study. EDET Study MICRONISED PURIFIED FLAVONOID FRACTION / Phase 4 Cardiovascular
IC4-05682-031 Detralex* versus placebo in the treatment of acute hemorrhoids in patients with acute hemorrhoidal attack.… MICRONISED PURIFIED FLAVONOID FRACTION / Phase 4 Cardiovascular
DM4-90652-001 Patient pREference and satisFaction for pErindopril oRodispersible vs convENtional tablets in daily Clinical practicE. PREFERENCE PERINDOPRIL / PERINDOPRIL ARGININE / Phase 4 Cardiovascular
DM4-20098-112 Clinical long-term effects of Valdoxan® (25 or 50 mg) in depressed patients. Clinical, national, interventional,… AGOMELATINE / AGOMELATINE - S020098 / S020098 / Phase 4 Neurosciences
DM4-20098-108 Clinical efficacy of VALDOXAN in everyday practice conditions (efficiency) in depressed patients, on a treatment-naive… AGOMELATINE / AGOMELATINE - S020098 / S020098 / Phase 4 Neurosciences

Servier clinical trials are mainly registered on


EU Clinical Trials Register

The EU Clinical Trials Register contains information on interventional clinical trials on medicines conducted in Europe, which started after 1 May 2004.

SEE MORE

ClinicalTrials.gov

Clinicaltrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

SEE MORE

ISRCTN registry

The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies.

SEE MORE
© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.